Verition Fund Management
STOK icon

Verition Fund Management’s Stoke Therapeutics STOK Stock Holding History

Verition Fund Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,055
Closed -$239K – 3988
2025
Q2 		$239K Buy
+21,055
New +$200K ﹤0.01% 3297
2025
Q1 		– Sell
-15,160
Closed -$167K – 3697
2024
Q4 		$167K Buy
+15,160
New +$186K ﹤0.01% 3015
2024
Q3 		– Sell
-44,205
Closed -$597K – 3502
2024
Q2 		$597K Buy
+44,205
New +$597K ﹤0.01% 1958
2023
Q4 		– Sell
-15,255
Closed -$60.1K – 2664
2023
Q3 		$60.1K Buy
+15,255
New +$100K ﹤0.01% 2170

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Verition Fund Management's STOK Position: Q3 2025 in Review

Verition Fund Management sold out of Stoke Therapeutics (STOK) in Q3 2025, closing a stake of 21,055 shares — an estimated $239K sold.

Verition Fund Management first reported a position in STOK in Q3 2023 and held it in 4 quarters. The position peaked at $597K in Q2 2024. 151 funds tracked by Wall St. Rank hold STOK as of Q3 2025.

  • Verition Fund Management reported no remaining Stoke Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 21,055 Stoke Therapeutics shares in Q3 2025, an estimated $239K.
  • Verition Fund Management first reported a position in Stoke Therapeutics in Q3 2023 and held it in 4 quarters.
  • Verition Fund Management's Stoke Therapeutics position peaked at $597K in Q2 2024.
  • 151 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.